vimarsana.com
Home
Live Updates
Fewer Than 1 in 4 Patients With HCV-Related HCC Get DAAs : vimarsana.com
Fewer Than 1 in 4 Patients With HCV-Related HCC Get DAAs
Early uncertainty about the safety of noninterferon antivirals in patients with liver cancer may have contributed to the slow acceptance of direct-acting antiviral agents in this population.
Related Keywords
Australia
,
University Of California San Francisco
,
California
,
United States
,
Boston
,
Massachusetts
,
Palo Alto
,
Stanford University
,
Steven Bollipo
,
Leslie Yeeman Kam
,
Comoderator Jennifer
,
Stanford University Medical Center
,
Liver Meeting
,
American Association
,
Liver Diseases
,
Clinformatics Data Mart
,
John Hunter Hospital
,
New South Wales
,
Medscape Medical
,
California San Francisco
,
Hepatitis C
,
Cv Hepatitisc Virus
,
Hepatocellular Carcinoma
,
Liver Cancer
,
Dcc
,
Hepatocellular Cancer
,
Ancer Liver
,
Ancer Hepatocellular
,
Hepatitis
,
Viral Hepatitis
,
Liver Disease
,
Liver
,
Cancer
,
Alignant Neoplasia
,
Arcinoma
,
Biliary Disease
,
Allbladder Disease
,
Decompensated Liver Disease
,
Antiviral
,
Amciclovir
,
Alacyclovir
,
Medical Literature
,
Books
,
Textbooks
,
Ournals
,
Clinical Research
,
,
vimarsana.com © 2020. All Rights Reserved.